Related Experiment Videos
[Minimally differentiated hypoplastic leukemia]
S Mitsuhashi1, T Nagasawa, M Kamoshita
1Division of Hematology, University of Tsukuba.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|February 1, 1995
Summary
This case study details a minimally differentiated hypoplastic acute myeloid leukemia (AML-M0) in an atomic bomb survivor. Treatment with BAM therapy reduced blasts but the patient succumbed to pneumonia.
Area of Science:
- Hematology
- Oncology
Background:
- Atomic bomb survivors face increased risks of radiation-related cancers, including leukemia.
- Hypoplastic acute myeloid leukemia (AML) presents with pancytopenia and a hypocellular bone marrow.
Observation:
- A 67-year-old female atomic bomb survivor presented with pancytopenia and a hypocellular bone marrow with 32.8% peroxidase-negative blasts.
- Immunophenotyping revealed CD2+, CD33+, CD34+, CD13+, CD3- blasts, consistent with AML-M0.
- Electron microscopy confirmed myeloperoxidase positivity.
Findings:
- The patient was diagnosed with minimally differentiated hypoplastic AML (AML-M0).
- BAM therapy was effective in reducing blast counts after a period of disease stability.
- The patient ultimately died from bacterial pneumonia during myelosuppression.
Implications:
- This case highlights the challenges in managing hypoplastic AML, particularly in radiation-exposed individuals.
- Early detection and appropriate therapeutic strategies are crucial for improving outcomes in rare AML subtypes.
- Further research into the long-term hematological effects of atomic radiation exposure is warranted.